| Renal Cell Carcinoma
Inlyta vs Temsirolimus - Temsirolimus
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Inlyta vs Temsirolimus with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTemsirolimus has a higher rate of injection site reactions vs Inlyta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Temsirolimus but not Inlyta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inlyta
Temsirolimus
At A Glance
Oral
Twice daily
VEGFR tyrosine kinase inhibitor
IV infusion
Once weekly
mTOR inhibitor
Indications
- Renal Cell Carcinoma
- Renal Cell Carcinoma
Dosing
Renal Cell Carcinoma (first-line, with avelumab) 5 mg orally twice daily combined with avelumab 800 mg IV every 2 weeks; dose escalation may be considered at intervals of 2 weeks or longer.
Renal Cell Carcinoma (first-line, with pembrolizumab) 5 mg orally twice daily combined with pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks IV; dose escalation may be considered at intervals of 6 weeks or longer.
Renal Cell Carcinoma (second-line, single agent) Starting dose 5 mg orally twice daily approximately 12 hours apart, with or without food; doses may be increased to 7 mg or 10 mg twice daily based on tolerability, or reduced to 3 mg or 2 mg twice daily for adverse reactions.
Advanced Renal Cell Carcinoma 25 mg administered as an intravenous infusion over a 30-60 minute period once weekly; continue until disease progression or unacceptable toxicity. Premedicate with IV diphenhydramine 25-50 mg approximately 30 minutes before each dose.
Dose Modification - Hepatic Impairment Reduce dose to 15 mg/week in patients with mild hepatic impairment (bilirubin >1-1.5x ULN or AST >ULN but bilirubin <=ULN); contraindicated if bilirubin >1.5x ULN.
Dose Modification - Strong CYP3A4 Inhibitors Avoid concomitant use; if unavoidable, reduce dose to 12.5 mg/week and allow approximately 1-week washout after inhibitor discontinuation before returning to prior dose.
Dose Modification - Strong CYP3A4 Inducers Avoid concomitant use; if unavoidable, increase dose from 25 mg/week up to 50 mg/week, then return to prior dose once inducer is discontinued.
Dose Modification - Toxicity Hold for ANC or platelet nadirs meeting threshold criteria or NCI CTCAE grade >=3 adverse reactions; once resolved to grade <=2, restart at dose reduced by 5 mg/week to no lower than 15 mg/week.
Contraindications
—
- Bilirubin >1.5x ULN
Adverse Reactions
Most common (>=20%) Diarrhea, fatigue, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, musculoskeletal pain, constipation
Serious Hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, hepatotoxicity
Postmarketing Arterial aneurysms, dissections, and rupture (including aortic)
Most common (>=30%) clinical adverse reactions Rash, asthenia, mucositis, nausea, edema, anorexia
Most common (>=30%) laboratory abnormalities Anemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, lymphopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphatemia, thrombocytopenia, elevated AST, leukopenia
Serious Hypersensitivity/infusion reactions, hepatic impairment, hyperglycemia/glucose intolerance, infections, interstitial lung disease, hyperlipidemia, bowel perforation, renal failure, wound healing complications, intracerebral hemorrhage
Postmarketing Angioedema, rhabdomyolysis, Stevens-Johnson Syndrome, complex regional pain syndrome (reflex sympathetic dystrophy), pancreatitis, cholecystitis, cholelithiasis, extravasation reactions (swelling, pain, warmth, erythema)
Pharmacology
Axitinib is a selective inhibitor of receptor tyrosine kinases including VEGFR-1, VEGFR-2, and VEGFR-3, which are implicated in pathologic angiogenesis, tumor growth, and cancer progression; VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models.
Temsirolimus binds to the intracellular protein FKBP-12, and the resulting protein-drug complex inhibits mTOR (mammalian target of rapamycin), blocking its ability to phosphorylate downstream effectors p70S6k and S6 ribosomal protein, leading to G1 growth arrest in tumor cells and reduced levels of HIF-1, HIF-2 alpha, and vascular endothelial growth factor.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inlyta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (9/12) · Qty limit (11/12)
Temsirolimus
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Inlyta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (3/8)
Temsirolimus
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Inlyta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (2/3)
Temsirolimus
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Renal Cell Carcinoma (RCC): Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Temsirolimus.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InlytaView full Inlyta profile
TemsirolimusView full Temsirolimus profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.